


PHARMACEUTICAL 2022



FIBROGEN INC Rank 355 of 466







PHARMACEUTICAL 2022



Rank 355 of 466

FIBROGEN INC

The relative strengths and weaknesses of FIBROGEN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIBROGEN INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 48% points. The greatest weakness of FIBROGEN INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 16%, being 62% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	474,059
Cost of Goods Sold	12,871
Intangible Assets	0
Liabilities, Current	225,497
Liabilities, Non-Current	301,595
Other Assets	271,485
Other Compr. Net Income	336
Other Expenses	347
Other Liabilities	17,616
Other Net Income	-1,146
Other Revenues	235,309
Property and Equipment	28,277
Research and Development	387,043
Selling, General and Administrative Expense	123,925

Output Variable	Value in 1000 USD
Assets	773,821
Liabilities	544,708
Expenses	524,186
Revenues	235,309
Stockholders Equity	229,113
Net Income	-290,023
Comprehensive Net Income	-289,855
Economic Capital Ratio	16%

